Clinical Trial Update: Dose-reduced Versus Standard Conditioning in MDS/sAML [Phase 3]

View source ↗

Summary

Phase 3 trial comparing dose-reduced versus standard conditioning in myelodysplastic syndromes and secondary acute myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Snippet

Sponsor: European Society for Blood and Marrow Transplantation | Conditions: Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED